Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 2/20 | 0.57 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.43 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | P4HB | P07237 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | NQO2 | P16083 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1476571 | 1.00 | RAF1 (0.57) | RAF1NPY5RPADI4CYP11B1CYP11B2 | |
| SCHEMBL1478735 | 0.83 | RAF1 (0.57) | RAF1CYP11B1CYP11B2PTGS1MAPT | |
| SCHEMBL1478736 | 0.83 | RAF1 (0.57) | RAF1CYP11B1CYP11B2PTGS1MAPT | |
| SCHEMBL1476902 | 0.83 | RAF1 (0.65) | RAF1PADI4CYP11B1CYP11B2AURKA | |
| SCHEMBL1476900 | 0.83 | RAF1 (0.65) | RAF1PADI4CYP11B1CYP11B2AURKA | |
| SCHEMBL1477006 | 0.78 | RAF1 (0.68) | RAF1P4HB | |
| SCHEMBL1477004 | 0.78 | RAF1 (0.68) | RAF1P4HB | |
| SCHEMBL28621230 | 0.78 | NFE2L2 (0.54) | NFE2L2PTGS1P4HBTP53 | |
| SCHEMBL14758485 | 0.78 | NFE2L2 (0.54) | NFE2L2PTGS1P4HBTP53 | |
| SCHEMBL6085958 | 0.74 | CYP11B2 (0.66) | NPY5RCYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915424-B2 | Analgesics; anxiolytic agents | ELI LILLY AND COMPANY (US) | 2011-03-29 | — | — | US | disclosed |
| EP-1729771-B1 | PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2009-10-14 | — | — | EP | disclosed |
| US-20080194647-A1 | Pyridyl Derivatives and Their Use as Mglu5 Antagonists | ELI LILLY AND COMPANY (US) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194647-A1 | Pyridyl Derivatives and Their Use as Mglu5 Antagonists | HRH4, CNR2, CNR1 | RAF1 4597/4885NPY5R 152/4885PADI4 1844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.